2003
DOI: 10.1016/s0142-9612(03)00351-x
|View full text |Cite
|
Sign up to set email alerts
|

Biomimetic design in microparticulate vaccines

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
12
0

Year Published

2005
2005
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 29 publications
(12 citation statements)
references
References 58 publications
0
12
0
Order By: Relevance
“…peptides, proteins, or nucleic acids, can be loaded into PLGA particles to achieve a controlled release and protection from degradation. However, the lack of functional groups on the surface of PLGA NPs for covalent modification has limited the potential for surface tethering bioactive molecules including DNA, ligands [3] or vaccines [4]. Thus, various attempts for physical surface modification of PLGA NPs have been made by coating PLGA with surfactants or polymers.…”
Section: Introductionmentioning
confidence: 99%
“…peptides, proteins, or nucleic acids, can be loaded into PLGA particles to achieve a controlled release and protection from degradation. However, the lack of functional groups on the surface of PLGA NPs for covalent modification has limited the potential for surface tethering bioactive molecules including DNA, ligands [3] or vaccines [4]. Thus, various attempts for physical surface modification of PLGA NPs have been made by coating PLGA with surfactants or polymers.…”
Section: Introductionmentioning
confidence: 99%
“…8 ͓The abbreviations used are MPS, mononuclear phagocytic system; APCs, antigen presenting cells; DCs, dendritic cells; M⌽, macrophages; PEG, poly͑ethylene glycol͒; PLL, poly-L-lysine; PLL͑x͒-g͓y͔-PEG͑z͒, copolymer of PEG ͑MW= z kDa͒ grafted to PLL ͑MW= x kDa͒ at a grafting ratio y; grafting ratio, g, number of lysine monomers divided by the number of PEG side chains; IgG, immunoglobulin G; PS, polystyrene; HEPES buffer, 10 mM 4-͑2-hydroxyethyl͒piperazine-1-ethane-sulfonic acid, pH 7.4; PBS buffer, 10 mM phosphate buffered saline, pH 7.4; RPMI medium, RPMI 1640 ͑Roswell Park Memorial Institute͒ with L-glutamine; and SSC, side scattering ͑measured by flow cytometry͒.͔ It is generally recognized that surface modifications of microparticulate antigen delivery systems with suitable peptides, proteins, oligosaccharides, or nucleic acids are of potential interest to control their first encounter with APC and could thus affect the type of immune response that will be elicited. [9][10][11][12] In order to specifically target APC, ligand mediated interactions with suitable receptors would be necessary.…”
Section: Introductionmentioning
confidence: 99%
“…Many studies now report that particles with diameters in both the nanometre and the micrometre range cross the small intestinal mucosal barrier and travel to other body sites (Volkheimer and Schultz, 1968;O'Hagan, 1990;Florence, 1997;Shreedhar et al, 2003;Keegan et al, 2003). Although the proportion of administered microparticles taken up may be low, the uptake of even small numbers of particles in this size range may have implications for human health in a variety of areas, such as drug or vaccine delivery, toxicology and immunology.…”
Section: Introductionmentioning
confidence: 99%